{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa+%28EB%29",
    "query": {
      "condition": "Epidermolysis Bullosa (EB)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa+%28EB%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T00:16:52.909Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05838092",
      "title": "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "allo-APZ2-OTS",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RHEACELL GmbH & Co. KG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 9,
      "start_date": "2023-10-18",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05838092"
    },
    {
      "nct_id": "NCT03158662",
      "title": "Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2017-04-02",
      "completion_date": "2017-06-30",
      "has_results": false,
      "last_update_posted_date": "2017-08-24",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 1,
      "location_summary": "Cranbury, New Jersey",
      "locations": [
        {
          "city": "Cranbury",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03158662"
    },
    {
      "nct_id": "NCT03529877",
      "title": "Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "allo-APZ2-EB",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "RHEACELL GmbH & Co. KG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "0 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2019-02-16",
      "completion_date": "2021-11-26",
      "has_results": false,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03529877"
    },
    {
      "nct_id": "NCT06834035",
      "title": "Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa",
        "Epidermolysis Bullosa Acquisita",
        "Dystrophic Epidermolysis Bullosa",
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Immunoglobulin G",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M. Peter Marinkovich",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2025-08-04",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06834035"
    },
    {
      "nct_id": "NCT02582775",
      "title": "MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Bone marrow infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Donor mesenchymal stem cell infusions",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 17,
      "start_date": "2016-03",
      "completion_date": "2023-07-26",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02582775"
    },
    {
      "nct_id": "NCT04031469",
      "title": "A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease",
      "overall_status": "SUSPENDED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gut Microbiome",
        "Gastrointestinal Microbiome",
        "Autism",
        "Autism Spectrum Disorder",
        "Autism Spectrum Disorder High-Functioning",
        "Alzheimer Disease",
        "Alzheimer Dementia (AD)",
        "Alzheimer Dementia",
        "Alzheimer Disease (AD)",
        "Crohn",
        "Crohn Colitis",
        "Crohn Disease (CD)",
        "Crohn Disease Colon",
        "Myalgic Encephalomyelitis",
        "ME/CFS",
        "Myalgic Encephalomyelitis (ME)",
        "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome",
        "Psoriasis",
        "Psoriasis Annularis",
        "Psoriasis Chronic",
        "Chronic Urinary Tract Infection",
        "Ulcerative Colitis (Disorder)",
        "Ulcerative Colitis (UC)",
        "Ulcerative Colitis Acute",
        "Ulcerative Colitis Chronic",
        "Multiple Sclerosis",
        "Multiple Sclerosis (MS) - Relapsing-remitting",
        "Multiple Sclerosis (MS) Primary Progressive",
        "Constipation Chronic Idiopathic",
        "Constipation",
        "Celiac",
        "Celiac Disease",
        "Celiac Sprue",
        "Lyme Arthritis",
        "Lyme Borreliosis, Nervous System",
        "Lyme Disease, Chronic",
        "Cholesterol",
        "Cholesterol Level, High",
        "Cancer",
        "Colon Cancer",
        "Amyotrophic Lateral Sclerosis (ALS)",
        "Amyotrophic Lateral Sclerosis",
        "Rheumatoid Arthritis (RA)",
        "Rheumatoid Arthritis - Rheumatism",
        "Chronic Fatigue Syndrome (CFS)",
        "PARKINSON DISEASE (Disorder)",
        "Parkinson Disease",
        "Parkinson Disease (PD)",
        "Depression",
        "Major Depressive Disorder (MDD)",
        "Depression Disorder",
        "Depression in Adults",
        "Anxiety",
        "Anxiety Disorder Generalized",
        "Obsessive Compulsive Disorder (OCD)",
        "Obsessive Compulsive Disorder OCD",
        "Obsessive - Compulsive Disorder",
        "Bipolar",
        "Bipolar 1 Disorder",
        "Bipolar Disorder (BD)",
        "Bipolar Disorder I and II",
        "Bipolar and Related Disorders",
        "Migraine",
        "Migraine Disorder",
        "Diabetes (DM)",
        "Diabetes",
        "Lupus",
        "Lupus Erythematosus",
        "Epidermolysis Bullosa (EB)",
        "Mesothelioma",
        "Mesothelioma Malignant",
        "IBS (Irritable Bowel Syndrome)",
        "Irritable Bowel",
        "IBS - Irritable Bowel Syndrome",
        "Irritable Bowel Syndrome (IBS)",
        "Eczema",
        "Eczema Atopic Dermatitis",
        "Acne",
        "Myasthaenia Gravis",
        "Gout"
      ],
      "interventions": [
        {
          "name": "There is no intervention in this study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2019-07-11",
      "completion_date": "2030-12-10",
      "has_results": false,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04031469"
    },
    {
      "nct_id": "NCT03605069",
      "title": "A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa Dystrophica, Recessive",
        "Epidermolysis Bullosa Dystrophica, Dominant"
      ],
      "interventions": [
        {
          "name": "QR-313",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phoenicis Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2018-07-02",
      "completion_date": "2018-12-17",
      "has_results": false,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03605069"
    },
    {
      "nct_id": "NCT03472287",
      "title": "To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epidermolysis Bullosa (EB)",
        "Epidermolysis Bullosa Simplex",
        "Dystrophic Epidermolysis Bullosa",
        "Junctional Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Diacerein 1% Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Castle Creek Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2018-05-18",
      "completion_date": "2019-02-14",
      "has_results": true,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472287"
    },
    {
      "nct_id": "NCT07011589",
      "title": "Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa (EB)",
        "Epidermolysis Bullosa Acquisita",
        "Recessive Dystrophic Epidermolysis Bullosa",
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Efgartigimod",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M. Peter Marinkovich",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2026-07",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07011589"
    },
    {
      "nct_id": "NCT00587223",
      "title": "Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa, Junctional",
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "Apligraf",
          "type": "DEVICE"
        },
        {
          "name": "Standard dressing regimen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Organogenesis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-12",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2010-06-29",
      "last_synced_at": "2026-07-23T00:16:52.909Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Miami, Florida • New York, New York + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587223"
    }
  ]
}